On September 18, 2019 Trobix Bio, a newly established start-up with a unique set of proprietary phage-based antibiotic resistance sensitizing solutions, reported that the Israel Innovation Authority (IIA) recently approved a grant for Trobix Bio to receive funding through the IIA "Early Stage Companies Incentive Program" (Press release, Trobix Bio, SEP 18, 2019, View Source [SID1234644363]). This funding will support the continuing development of novel products that abolish bacterial antibiotic resistance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The IIA, previously known as the Office of the Chief Scientist of Israel’s Ministry of Economy, is an independent publicly funded agency, which acts as the support arm of the Israeli government to help facilitate the development of industrial R&D within the State of Israel.

"Trobix Bio is pioneering the development of products to treat the global crisis of antimicrobial resistance, and the support of our program by the IIA is proof of their confidence in the potential of Trobix Bio to combat antibiotic resistance with our unique technology," said Dr. Adi Elkeles, Founder and CEO of Trobix Bio. "We are grateful for the financial support from the IIA, which complements our seed funding that was completed in March 2019, thus enabling us to spring board the development of our initial product pipeline."